Teva, Active Biotech Enroll Patients in Laquinimod Trial

November 7, 2007

Israel’s Teva Pharmaceutical and Sweden’s Active Biotech have started enrollment in a Phase III trial of oral laquinimod for the treatment of relapsing-remitting multiple sclerosis.

Allegro is a double-blind study designed to evaluate the efficacy, safety and tolerability of laquinimod versus placebo. The trial will enroll approximately 1,000 patients, Active Biotech said.

Laquinimod also will be studied in the Phase III BRAVO trial, which is expected to begin enrollment in the first quarter of 2008. BRAVO is a multinational, multicenter, randomized, parallel-group, placebo-controlled study comparing the effects of laquinimod with placebo. The study will enroll approximately 1,200 participants who will be followed for 24 months.